EZH2 and melanoma: In different studies, overexpression of EZH2 has been identified as a biomarker of aggressive and highly proliferating tumors and is, hence, being associated with worse patient outcome, e.g., in endometrial, prostate, and breast cancer as well as melanoma (Bachmann et al. 2006).